Oculis Holding AG

Rentabilité sur six mois: -13.94%
Rendement en dividendes: 0%
Secteur: Healthcare

19.02 $

0 $ 0%
10.94 $
22.91 $

paper.min_max_per_year

Calendrier des promotions Oculis Holding AG

À propos de l'entreprise Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Paramètres de base

IPO date
2023-03-02
ISIN
CH1242303498
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
chf
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 317.87 1
P/BV 9.18 1
P/E 0 0
Efficacité
Nom Signification Grade
ROA -73.09 0
ROE -102.66 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0258 10
Debt/Ratio 0.0098 10
Debt/Equity 0.6401 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -11.08 0
Rentabilité Ebitda, % 277.99 10
Rentabilité EPS, % 282.88 10

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 19.02 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 19.79 $ 0 $ 0 $ -3.89 % 0 % 0 %
common.calendar.number_days.30d 19.01 $ 19.02 $ 19.92 $ 0.05 % 0 % 0 %
common.calendar.number_days.90d 16.75 $ 14.8 $ 19.92 $ 13.55 % 0 % 0 %
common.calendar.number_days.180d 22.1 $ 14.37 $ 22.91 $ -13.94 % 0 % 0 %
common.calendar.number_days.1y 12.05 $ 10.94 $ 22.91 $ 57.84 % 0 % 0 %
common.calendar.number_days.3y 9.86 $ 6.99 $ 22.91 $ 92.9 % 0 % 0 %
common.calendar.number_days.5y 6.99 $ 6.99 $ 22.91 $ 272.1 % 0 % 0 %
common.calendar.number_days.10y 6.99 $ 6.99 $ 22.91 $ 272.1 % 0 % 0 %
common.calendar.number_days.ytd 22.91 $ 14.37 $ 22.91 $ -16.98 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Riad Sherif M.B.A., M.D. CEO & Director N/A 1968 (57 années)
Ms. Sylvia Cheung Chief Financial Officer N/A 1975 (50 années)
Mr. Páll Ragnar Jóhannesson Chief Business Officer N/A 1982 (43 année)
Ms. Rebecca Weil Chief Commercial Officer N/A
Dr. Ramin Tadayoni M.D., Ph.D. Chief Scientific Officer N/A
Ms. Virginia R. Dean Chief Human Resources Officer N/A 1967 (58 années)
Dr. Bastian Dehmel M.D. Chief Development Officer N/A 1971 (54 année)
Dr. Snehal Shah Pharm.D. President of Research & Development N/A
Dr. Sharon Klier M.D., M.P.H. Chief Development Officer

Informations sur l'entreprise

Adresse: Switzerland, Zug, Bahnhofstrasse 7 - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://oculis.com